Drug Profile
Research programme: small molecule therapeutics: Boehringer/TransTech
Latest Information Update: 23 Sep 2010
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; TransTech Pharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 23 Sep 2010 No development reported - Preclinical for Undefined indication in USA (unspecified route)
- 23 Dec 2005 Preclinical trials in Undefined in USA (unspecified route)